公开(公告)号：EP0866710A1

公开(公告)日：1998-09-30

申请号：EP96936906.0

申请日：1996-10-23

申请人： ZymoGenetics, Inc. ,  Osteoscreen, Inc. ,  University Of Texas At Austin

发明人： PETRIE, Charles ,  ORME, Mark, W. ,  BAINDUR, Nand ,  ROBBINS, Kirk, G. ,  HARRIS, Scott, M. ,  KONTOYIANNI, Maria ,  HURLEY, Laurence, H. ,  KERWIN, Sean, M. ,  MUNDY, Gregory, R.

IPC分类号： C07D285 ,  A61K31

CPC分类号： A61K31/549 ,  A61K31/47

摘要： Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or 'linker' defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15Å, are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.

公开(公告)号：EP0973513A1

公开(公告)日：2000-01-26

申请号：EP97912787.5

申请日：1997-10-23

申请人： zymogenetics, Inc. ,  Osteoscreen, Inc. ,  University of Texas Austin

发明人： ORME, Mark, W. ,  BAINDUR, Nand ,  ROBBINS, Kirk, G. ,  HARRIS, Scott, M. ,  KONTOYIANNI, Maria ,  HURLEY, Laurence, H. ,  KERWIN, Sean, M. ,  MUNDY, Gregory, R. ,  PETRIE, Charles

IPC分类号： A61K31/165 ,  A61K31/215 ,  A61K31/33 ,  A61K31/405 ,  A61K31/415 ,  A61K31/42 ,  A61K31/425 ,  A61K31/44 ,  A61K31/47 ,  A61K31/505 ,  A61K31/53

CPC分类号： A61K31/655 ,  A61K31/196 ,  A61K31/4184 ,  A61K31/428 ,  A61K31/444 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/517 ,  A61K31/53

摘要： Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or 'linker' defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15Å, are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.